Carmine Stengone's most recent trade in Kiora Pharmaceuticals Inc was a trade of 20,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | Carmine Stengone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc... | Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Carmine Stengone | Director | Purchase of securities on an exchange or from another person at price $ 3.68 per share. | 11 Sep 2024 | 1,250 | 1,250 (0%) | 0% | 3.7 | 4,600 | Common Stock |
| Kiora Pharmaceuticals Inc | Carmine Stengone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc... | Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 285,000 | 285,000 | - | - | Stock Option (right to buy) |